Lilly ad campaign offers diabetes med help for amid pandemic by Beth Snyder Bulik Tuesday, March 31, 2020 Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.
AZ halts Farxiga kidney disease trial by Kyle Blankenship Monday, March 30, 2020 AstraZeneca has halted its phase 3 Farxiga trial in chronic kidney disease––a move that could soon spell an FDA approval in the major market.
ACC: AZ's Farxiga shows CV benefits regardless of prior therapy by Kyle Blankenship Saturday, March 28, 2020 AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.
FDA blocks Lilly, Boehringer's Jardiance in Type 1 diabetes by Kyle Blankenship Monday, March 23, 2020 Boehringer and Lilly's Jardiance is locked in a Type 2 diabetes battle against its SGLT2 rivals, and a leg up in Type 1 now doesn't appear likely.
Lilly, BI's Jardiance nabs speedy FDA review in kidney disease by Kyle Blankenship Thursday, March 12, 2020 Aiming to keep pace with its SGLT2 rivals in kidney disease, Lilly and Boehringer's Jardiance scored a speedy FDA review in the indication.
Major drugmakers likely to benefit from heart failure gold rush by Kyle Blankenship Tuesday, January 21, 2020 An SGLT2 arms race is currently underway for heart failure patients, and not without reason: the market will likely continue to boom this decade.
Novo's Ozempic scores major win with heart-helping FDA approval by Kyle Blankenship Friday, January 17, 2020 Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.
AstraZeneca's Farxiga speeds toward pioneering CV approval by Kyle Blankenship Monday, January 6, 2020 With a nod in heart failure patients already secured, AstraZeneca's Farxiga has now landed a priority review in patients with or without diabetes.
Lilly, BI's Jardiance whiffs in CV trial chasing Farxiga by Kyle Blankenship Friday, December 13, 2019 Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.
AHA: Lilly, BI's Jardiance drops CV hospitalizations over rivals by Kyle Blankenship Sunday, November 17, 2019 In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.
